Compare Sanofi SA (SNY) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TORM plc — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while TORM plc trades at $33.8 (market cap $3.58B). The key difference: Sanofi SA is far larger — about 29.1× TORM plc's market cap, and TORM plc pays the higher dividend (12.65%). Which is the better fit depends on your goals.
| SNY | TRMD | |
|---|---|---|
Market Cap | $104.06B | $3.58B |
Sector | Health | Technology |
52-Week High | $52.34 | $35.46 |
52-Week Low | $41.33 | $19.39 |
Enterprise Value | $124.09B | $4.28B |
Dividend Yield | 5.61% | 12.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
TRMD trades at $34.94, down 0.68% today, with a bullish technical signal from moving averages and strong support at $34. The company reported record Q2 2026 earnings with $3.25 EPS, though slightly missing estimates, and maintains robust profitability with a 35.52% net margin. Recent news highlights a capital increase from RSU exercises and a strong dividend of $2.40 payable in September 2026.
Outlook is positive with 100% analyst buy ratings, underpinned by strong cash flow growth and high ROE of 26.84%. Risks include reliance on volatile freight rates and potential market corrections given elevated RSI levels. The stock presents value with a low P/E of 5.75, but investors should monitor earnings consistency and global trade dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
